Association of spermidine plasma levels with brain aging in a population-based study

Silke M. Wortha, Stefan Frenzel, Martin Bahls, Mohamad Habes, Katharina Wittfeld, Sandra Van der Auwera, Robin Bülow, Stephanie Zylla, Nele Friedrich, Matthias Nauck, Henry Völzke, Hans J. Grabe, Claudia Schwarz, Agnes Flöel

Resultado de la investigación: Articlerevisión exhaustiva


Introduction: Supplementation with spermidine may support healthy aging, but elevated spermidine tissue levels were shown to be an indicator of Alzheimer's disease (AD). Methods: Data from 659 participants (age range: 21–81 years) of the population-based Study of Health in Pomerania TREND were included. We investigated the association between spermidine plasma levels and markers of brain aging (hippocampal volume, AD score, global cortical thickness [CT], and white matter hyperintensities [WMH]). Results: Higher spermidine levels were significantly associated with lower hippocampal volume (ß = −0.076; 95% confidence interval [CI]: −0.13 to −0.02; q = 0.026), higher AD score (ß = 0.118; 95% CI: 0.05 to 0.19; q = 0.006), lower global CT (ß = −0.104; 95% CI: −0.17 to −0.04; q = 0.014), but not WMH volume. Sensitivity analysis revealed no substantial changes after excluding participants with cancer, depression, or hemolysis. Discussion: Elevated spermidine plasma levels are associated with advanced brain aging and might serve as potential early biomarker for AD and vascular brain pathology.

Idioma originalEnglish (US)
PublicaciónAlzheimer's and Dementia
EstadoAccepted/In press - 2022

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Clinical Neurology
  • Geriatrics and Gerontology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health


Profundice en los temas de investigación de 'Association of spermidine plasma levels with brain aging in a population-based study'. En conjunto forman una huella única.

Citar esto